Future perspectives in melanoma research

[1]  K. Abromeit.  Music Received , 2023, Notes.

[2]  J. Wolchok,et al.  T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Puzanov,et al.  Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Chin,et al.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.

[5]  C. Croce,et al.  Abstract 1070: miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma , 2016 .

[6]  M. Sabatino,et al.  Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. , 2016, Cytotherapy.

[7]  J. Wolchok,et al.  Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient , 2016, The Journal of experimental medicine.

[8]  B. Fox,et al.  Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine , 2016, Journal of Immunotherapy for Cancer.

[9]  H. Kohrt,et al.  Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. , 2016, The Journal of investigative dermatology.

[10]  H. Zarour.  Reversing T-cell Dysfunction and Exhaustion in Cancer , 2016, Clinical Cancer Research.

[11]  Xiaoxiao Wang,et al.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. , 2016, Cancer cell.

[12]  R. Dummer,et al.  Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. , 2016, European journal of cancer.

[13]  H. Kohrt,et al.  Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. , 2016, The Journal of clinical investigation.

[14]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[15]  C. Ferrone,et al.  Intracellular antigens as targets for antibody based immunotherapy of malignant diseases , 2015, Molecular oncology.

[16]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[17]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[18]  R. Dummer,et al.  The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.

[19]  S. Demaria,et al.  TGFβ and activin A control regulatory T cells in irradiated tumors , 2015, Journal of Immunotherapy for Cancer.

[20]  P. Ascierto,et al.  A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence , 2015, Journal of Immunotherapy for Cancer.

[21]  C. Dubay,et al.  Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC , 2015, Journal of Immunotherapy for Cancer.

[22]  S. Demaria,et al.  Abscopal Responses in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated on a Phase 2 Study of Combined Radiation Therapy and Ipilimumab: Evidence for the In Situ Vaccination Hypothesis of Radiation , 2015 .

[23]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[24]  J. Kirkwood,et al.  Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma , 2015, Journal of Immunotherapy for Cancer.

[25]  Antoni Ribas,et al.  Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance , 2015, Cell.

[26]  Kathleen R. Cho,et al.  Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy , 2015, Nature.

[27]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.

[28]  yang-xin fu,et al.  CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.

[29]  R. Emerson,et al.  Abstract 2856: Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade , 2015 .

[30]  S. Ariyan,et al.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.

[31]  L. Fattore,et al.  Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma , 2015, Oncotarget.

[32]  C. Horak,et al.  Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. , 2015, JAMA oncology.

[33]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[34]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[35]  C. Robert,et al.  Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. , 2015, Seminars in oncology.

[36]  G. Linette,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[38]  J. Lunceford,et al.  Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. , 2015 .

[39]  J. Lunceford,et al.  Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. , 2015 .

[40]  J. Nemunaitis,et al.  Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. , 2015 .

[41]  R. Berger,et al.  Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Tarhini.  Neoadjuvant therapy for melanoma: a promising therapeutic approach and an ideal platform in drug development. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[43]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[44]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[45]  Joe-Marc Chauvin,et al.  TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. , 2015, The Journal of clinical investigation.

[46]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[47]  J. Massagué,et al.  Therapy-induced tumour secretomes promote resistance and tumour progression , 2015, Nature.

[48]  P. Altevogt,et al.  Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment , 2015, Oncoimmunology.

[49]  R. Dummer,et al.  Curing advanced melanoma by 2025. , 2015, Current opinion in oncology.

[50]  J. Larkin,et al.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.

[51]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  K. Flaherty,et al.  Gauging the Long-Term Benefits of Ipilimumab in Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[54]  S. Agarwala.  Intralesional therapy for advanced melanoma: promise and limitation , 2015, Current opinion in oncology.

[55]  R. Childs,et al.  CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo , 2015, Cancer Immunology, Immunotherapy.

[56]  R. Dummer,et al.  The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors , 2015, Nature Communications.

[57]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[58]  X. Wang,et al.  Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma , 2015, Journal of Translational Medicine.

[59]  M. Okoniewski,et al.  In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma , 2015, Oncoimmunology.

[60]  Kakajan Komurov,et al.  Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. , 2014, Cancer research.

[61]  R. Emerson,et al.  Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade , 2014, Journal of Immunotherapy for Cancer.

[62]  A. Sarnaik,et al.  Efficacy of intralesional injection with PV-10 in combination with co-inhibitory blockade in a murine model of melanoma , 2014, Journal of Immunotherapy for Cancer.

[63]  J. Nemunaitis,et al.  1103PCALM STUDY: SECONDARY ENDPOINTS OF A PHASE II STUDY OF A NOVEL ONCOLYTIC IMMUNOTHERAPEUTIC AGENT, COXSACKIEVIRUS A21, DELIVERED INTRATUMORALLY IN PATIENTS WITH ADVANCED MALIGNANT MELANOMA. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  P. Fox,et al.  Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations , 2014, Clinical Cancer Research.

[65]  J. Berzofsky,et al.  Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway , 2014, Cancer Immunology Research.

[66]  A. Ribas,et al.  Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Etienne Rouleau,et al.  Guidance for laboratories performing molecular pathology for cancer patients , 2014, Journal of Clinical Pathology.

[68]  Frank McCormick,et al.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.

[69]  J. Kirkwood,et al.  Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). , 2014 .

[70]  K. Aldape,et al.  Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target , 2014, Clinical Cancer Research.

[71]  M. Gore,et al.  Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. , 2014, The Lancet. Oncology.

[72]  G. Freeman,et al.  Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade , 2014, Cancer Immunology Research.

[73]  Russell Weiner,et al.  Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics , 2014, Front. Oncol..

[74]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[75]  F. Fulciniti,et al.  Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma , 2014, Cancer Immunology, Immunotherapy.

[76]  S. Demaria,et al.  Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death , 2014, Oncoimmunology.

[77]  J. Wolchok,et al.  Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.

[78]  J. Kirkwood,et al.  Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab , 2014, PloS one.

[79]  C. Yee.  The use of endogenous T cells for adoptive transfer , 2014, Immunological reviews.

[80]  Hong Wang,et al.  PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. , 2013, Cancer research.

[81]  David E Fisher,et al.  BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes , 2013, Oncoimmunology.

[82]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[83]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[84]  L. Fattore,et al.  Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies , 2013, Journal of Translational Medicine.

[85]  Joshua L. Deignan,et al.  ACMG clinical laboratory standards for next-generation sequencing , 2013, Genetics in Medicine.

[86]  S. Mocellin,et al.  Interferon alpha for the adjuvant treatment of cutaneous melanoma. , 2013, The Cochrane database of systematic reviews.

[87]  K. Flaherty,et al.  BRAF in Melanoma: Current Strategies and Future Directions , 2013, Clinical Cancer Research.

[88]  P. Allavena,et al.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions , 2013, Seminars in Immunopathology.

[89]  S J Cook,et al.  Mechanisms of acquired resistance to ERK1/2 pathway inhibitors , 2013, Oncogene.

[90]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[91]  J. Kirkwood,et al.  IFN-α in the Treatment of Melanoma , 2012, The Journal of Immunology.

[92]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[93]  D. Schadendorf,et al.  Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  A. Ribas,et al.  Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7) , 2012 .

[95]  S. Demaria,et al.  Role of T lymphocytes in tumor response to radiotherapy , 2012, Front. Oncol..

[96]  Veronica Huber,et al.  Recent advances on the role of tumor exosomes in immunosuppression and disease progression. , 2012, Seminars in cancer biology.

[97]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[98]  F. Marincola,et al.  A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon , 2012, PloS one.

[99]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[100]  B. Fox,et al.  Increased Frequency of Suppressive Regulatory T Cells and T Cell-Mediated Antigen Loss Results in Murine Melanoma Recurrence , 2012, The Journal of Immunology.

[101]  Daohai Yu,et al.  Biomarkers on melanoma patient T Cells associated with ipilimumab treatment , 2012, Journal of Translational Medicine.

[102]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[103]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[104]  R. Elashoff,et al.  Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I) , 2012, Annals of Surgical Oncology.

[105]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[106]  H. Uno,et al.  Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: Effect of specimen source (bone marrow or peripheral blood) on assay readouts , 2012, Cytometry. Part B, Clinical cytometry.

[107]  Mehdi Nosrati,et al.  Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis , 2012, Proceedings of the National Academy of Sciences.

[108]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[109]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[110]  C. Yee,et al.  Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype , 2012, Proceedings of the National Academy of Sciences.

[111]  Ornella Pagliano,et al.  CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. , 2012, Cancer research.

[112]  Jeffrey E. Lee,et al.  Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma , 2012, Annals of surgery.

[113]  J. Kirkwood,et al.  Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  I. Weissman,et al.  Programmed cell removal: a new obstacle in the road to developing cancer , 2011, Nature Reviews Cancer.

[115]  J. Yewdell,et al.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. , 2011, Trends in immunology.

[116]  J. Wolchok,et al.  Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab , 2011, Proceedings of the National Academy of Sciences.

[117]  B. Fox,et al.  Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism , 2011, Clinical Cancer Research.

[118]  I. V. D. van der Ploeg,et al.  Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  A. Melcher,et al.  Thunder and lightning: immunotherapy and oncolytic viruses collide. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[120]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[121]  S. Loi,et al.  Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy , 2011, Proceedings of the National Academy of Sciences.

[122]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[123]  Zlatko Trajanoski,et al.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  J. Lane,et al.  Measuring the Results of Science Investments , 2011, Science.

[125]  J. Boudreau,et al.  Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[126]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[127]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[128]  A. Stromberg,et al.  Ulceration as a Predictive Marker for Response to Adjuvant Interferon Therapy in Melanoma , 2010, Annals of surgery.

[129]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[130]  M. Greene,et al.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. , 2010, Cancer cell.

[131]  D. Heimbrook,et al.  RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. , 2010, Cancer research.

[132]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[133]  C. Nutting,et al.  A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  P. Ascierto,et al.  Melanoma: A model for testing new agents in combination therapies , 2010, Journal of Translational Medicine.

[135]  Z. Trajanoski,et al.  Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. , 2010, Gastroenterology.

[136]  C. Garlanda,et al.  An integrated view of humoral innate immunity: pentraxins as a paradigm. , 2010, Annual review of immunology.

[137]  E. Tartour,et al.  Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.

[138]  K. Zatloukal,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  K. Harrington,et al.  Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[141]  Daniel J Sargent,et al.  Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  R. Fahsold,et al.  Independent NF1 and PTPN11 mutations in a family with neurofibromatosis‐Noonan syndrome , 2009, American journal of medical genetics. Part A.

[143]  S. Rosenberg,et al.  Adoptive cell therapy for the treatment of patients with metastatic melanoma. , 2009, Current opinion in immunology.

[144]  A. Eggermont,et al.  Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients: A Multicenter Study in 388 Patients With Positive Sentinel Nodes , 2008, Annals of surgery.

[145]  P. Ascierto,et al.  Adjuvant therapy of melanoma with interferon: lessons of the past decade , 2008, Journal of Translational Medicine.

[146]  W. Urba,et al.  Efficient cross-presentation depends on autophagy in tumor cells. , 2008, Cancer research.

[147]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[148]  Donna Niedzwiecki,et al.  Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  D. Palli,et al.  Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. , 2007, Clinical immunology.

[150]  L. Mariani,et al.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  Serban Nacu,et al.  Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma , 2007, PLoS medicine.

[152]  J. Galon,et al.  The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. , 2007, Cancer research.

[153]  H. Fukuhara,et al.  Oncolytic herpes simplex virus type 1 and host immune responses. , 2007, Current cancer drug targets.

[154]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[155]  C. Dinarello,et al.  Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression , 2006, Cancer and Metastasis Reviews.

[156]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[157]  D. Jukic,et al.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  D. Barford,et al.  PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects* , 2006, Journal of Biological Chemistry.

[159]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[160]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[161]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[162]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[163]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.

[164]  C. Yee,et al.  IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response1 , 2005, The Journal of Immunology.

[165]  S. Libutti,et al.  Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[167]  S. Rosenberg,et al.  Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy , 2005, Journal of immunotherapy.

[168]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.

[169]  William J. Gradishar,et al.  Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer , 2004, Clinical Cancer Research.

[170]  Lieping Chen.  Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.

[171]  B. Fox,et al.  Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.

[172]  D. Elder,et al.  Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. , 2003, European journal of cancer.

[173]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[174]  G. Dranoff.  GM-CSF-secreting melanoma vaccines , 2003, Oncogene.

[175]  R. Coffin,et al.  ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties , 2003, Gene Therapy.

[176]  S. Rabkin,et al.  Oncolytic herpes simplex virus vectors for cancer virotherapy , 2002, Cancer Gene Therapy.

[177]  D. Dunson,et al.  Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. , 2002, Cancer research.

[178]  D. Girling.  Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial , 2002, The Lancet.

[179]  V. Sondak,et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  G. Fantuzzi,et al.  IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[181]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[182]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[184]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.

[185]  T. Gajewski,et al.  Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. , 2016, Advances in immunology.

[186]  Yongliang Zhang,et al.  GRP94/gp96 in Cancer: Biology, Structure, Immunology, and Drug Development. , 2016, Advances in cancer research.

[187]  M. Coffey,et al.  Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[188]  J. Wolchok,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[189]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[190]  Antoni Ribas,et al.  A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. , 2014, Cancer discovery.

[191]  D. Schadendorf,et al.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. , 2012, European journal of cancer.

[192]  J. Q. Rosso,et al.  Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients: A Multicenter Study in 388 Patients With Positive Sentinel Nodes , 2010 .

[193]  S. Mocellin,et al.  Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. , 2010, Journal of the National Cancer Institute.

[194]  S. Aamdal,et al.  Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. , 2003, European journal of cancer.

[195]  D. Kirn,et al.  Oncolytic biotherapy: a novel therapeutic plafform. , 2002, The Lancet. Oncology.

[196]  J C Briggs,et al.  Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.